Amundi Alkermes Plc. Transaction History

Amundi

$253 Billion
Q2 2024

A detailed history of Amundi transactions in Alkermes Plc. stock. As of the latest transaction made, Amundi holds 336,685 shares of ALKS stock, worth $9.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

336,685

Previous 308,672 9.08%

Holding current value

$9.27 Million

Previous $8.36 Million 2.88%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$23.21 - $27.24 $650,181 - $763,074	28,013 Added 9.08%	336,685 $8.11 Million
Q1 2024 May 15, 2024	BUY	$26.4 - $32.56 $4.86 Million - $5.99 Million	184,014 Added 147.62%	308,672 $8.36 Million
Q4 2023 Feb 14, 2024	BUY	$23.37 - $28.68 $29,165 - $35,792	1,248 Added 1.01%	124,658 $3.46 Million
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $2.95 Million - $3.47 Million	108,554 Added 730.71%	123,410 $3.46 Million
Q2 2023 Aug 14, 2023	SELL	$28.34 - $33.63 $92,926 - $110,272	-3,279 Reduced 18.08%	14,856 $464,000
Q1 2023 May 15, 2023	BUY	$25.31 - $29.02 $62,895 - $72,114	2,485 Added 15.88%	18,135 $511,000
Q4 2022 Feb 14, 2023	SELL	$21.94 - $26.24 $1.53 Million - $1.83 Million	-69,635 Reduced 81.65%	15,650 $408,000
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $1.88 Million - $2.72 Million	85,285 New	85,285 $1.97 Million
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $1.73 Million - $2.59 Million	-80,703 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$23.37 - $32.13 $398,809 - $548,298	-17,065 Reduced 17.45%	80,703 $2.49 Million
Q2 2021 Aug 16, 2021	BUY	$18.78 - $25.15 $1.84 Million - $2.46 Million	97,768 New	97,768 $2.4 Million

Others Institutions Holding ALKS

# of Institutions

346

Shares Held

183M

Call Options Held

209K

Put Options Held

89.4K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.52B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account